ICD-10 Coding for Pheochromocytoma(C74.1, C74.1M, C74.1N)

Comprehensive guide on ICD-10 coding for pheochromocytoma, including malignant and benign classifications, documentation requirements, and billing considerations.

Also known as:
Adrenal medulla tumorChromaffin cell tumor
Related ICD-10 Code Ranges

Complete code families applicable to Pheochromocytoma

Code Comparison: When to Use Each Code

Compare key differences between these codes to ensure accurate selection

CodeDescription
C74.1Malignant neoplasm of adrenal medulla
D35.00Benign neoplasm of adrenal gland, unspecified

Clinical Decision Support

Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.

Key Information

Essential facts and insights aboutPheochromocytoma

Differential Codes

Alternative codes to consider when ruling out similar conditions

Benign neoplasm of adrenal gland, unspecifiedD35.00

Use when the tumor is confirmed benign without invasion.

Malignant neoplasm of adrenal medullaC74.1

Use when malignancy is confirmed.

Documentation & Coding Risks

Avoid these common issues when documenting Pheochromocytoma.

Omitting secondary hypertension code

Impact

Clinical: Incomplete clinical picture of the patient's condition., Regulatory: Non-compliance with coding guidelines., Financial: Potential loss of reimbursement for related treatments.

Mitigation

Review patient history for hypertension, Ensure linkage to pheochromocytoma in documentation

Coding benign pheochromocytoma as malignant without confirmation

Impact

Reimbursement: Incorrect coding can lead to overpayment or claim denial., Compliance: Non-compliance with ICD-10 guidelines., Data Quality: Inaccurate clinical data affecting patient records.

Mitigation

Ensure pathology reports confirm malignancy before coding as C74.1.

Malignant vs. benign coding

Impact

Risk of misclassification affecting reimbursement and compliance.

Mitigation

Require pathology confirmation before coding malignancy.

Frequently Asked Questions